DURHAM, N.C., United States and BEIJING, China – August 29, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in September 2022. Details of the conference and management presentations are as follows:
HKEX Biotech Summit 2022
Investor Meetings: September 1, 2022
Participants: Management team and IR
For more information, please visit the official event webpage.
Morgan Stanley 20th Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 14, 2022, 1:30pm ET
Investor Meetings: September 14, 2022
Participants: Management team and IR
For more information, please contact your Morgan Stanley representative.
H.C. Wainwright 24th Annual Global Investment Conference
Fireside Chat On-Demand available on Monday, September 12, 7:00am ET
Investor Meetings: September 12 – 14, 2022
Participants: Management team and IR
For more information, please contact your H.C. Wainwright representative.
Citi 2022 China Healthcare Corporate Day
Investor Meetings: September 20 – 21, 2022
Participants: Management team and IR
For more information, please contact your Citi representative.
About Brii Bio
Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.
Media Inquiry:
media@briibio.com
Summer Li (China)
+86-135-2191-1607
Darcie Robinson (U.S.)
+1-203-919-7905
Investor Inquiry:
ir@briibio.com
Chris Fang
+86-139-1692-8049
